|Articles|June 1, 2002

Introduction: Considering Your Quinolone Formulary Options: An overview of Ciprofloxacin and Moxifloxacin

This Managed Healthcare Executive supplement was produced through an unrestristed educational grant from Bayer Corporation. The views and opinions in this supplement are those of the faculty and do not necessarily reflect the views of Managed Healthcare Executive, Advanstar Communications Inc., or Advanstar Medical Education Services. Copyright 2002 Advanstar Communications Inc. All rights reserved.

Newsletter

Get the latest industry news, event updates and more from Managed Healthcare Executive.

Subscribe

Latest CME

Multimedia

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Jonathan Goldman, MD; Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Ignacio I. Wistuba, MD

Introduction: Considering Your Quinolone Formulary Options: An overview of Ciprofloxacin and Moxifloxacin

Related Content

Adverse drug events after hospitalization: 'These are the sickest people that we have who are not in the hospital'

Putting pharmacists in charge of medication management as patients leave the hospital seems like a good idea. Does it work?

The Great Healthcare Plan, MFN drug prices and the political implications of the end of ACA enhanced subsidies: Here are 7 takeaways from the MHE-AJMC webinar

8 things you need to understand about tariffs on pharmaceuticals and other healthcare products after last week’s Supreme Court ruling

7 things you need to know about the PBM reforms signed into law this week

Latest CME

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

27th Annual International Lung Cancer Congress®

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

26th Annual International Lung Cancer Congress

Tennessee Oncology Practice Society

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

9th Annual School of Nursing Oncology™

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

20th Annual New York Lung Cancers Symposium®

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Trending on Managed Healthcare Executive

Medicare Advantage enrollees more likely to leave after new complex diagnosis

FDA approves Mounjaro to reduce cardiovascular risk in Type 2 diabetes

FDA approves Gilead’s Bixlenvo, smallest single-tablet option for virologically suppressed HIV patients

FDA approves brepocitinib for rare skin disease

Real-World Safety Experience and Clinical Takeaways from the BE BOLD Trial